US Patent 8,648,093: Scope of Claims, Enforceable Coverage, and Landscape

US Patent 8,648,093 is a composition-and-use patent built around a single defined active ingredient (a quinolinecarboxylate salt of a substituted dihydro-quinolinone-like core) presented in two specific solid forms (crystalline anhydrous and crystalline trihydrate), formulated with a broadly open excipient list, and used to treat bacterial infections in fish or mammals.

What matters for enforcement is that the independent coverage is not limited by route, species (fish vs mammal), or dose range. The scope narrows only when claim features add specific solid-form characterization (powder diffraction, lattice parameters, and purity thresholds).

What do the asserted claim elements cover?

1) Core active ingredient identity (salt forms)

All compositions are built around:

Anhydrous salt (Claim 1):
D-Glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate salt (generic “D-glucitol” refers to the counterion/stoichiometric partner as written in the claim)
Trihydrate salt (Claim 14): same salt, but explicitly trihydrate

This creates two enforceable “buckets”:

anhydrous crystalline material (Claims 1-13)
trihydrate crystalline material (Claims 14-26)

2) Formulation coverage (open excipient selection)

Claims 1 and 14 cover “therapeutic composition” formed by:

the defined salt
plus an excipient selected from a very long list

The excipient list is effectively open-ended by design because it is phrased as “selected from the group consisting of” and then enumerates dozens of common pharmaceutical excipients and carriers, followed by “and mixtures thereof.” The claim language does not impose functional restrictions like pH, ionic strength, or release profile.

Operational implication: products that match the salt form and use only excipients inside the enumerated set fall within the formulation claim even if they differ in manufacturing details.

3) Solid-form characterization layers (crystalline, purity, diffraction, lattice parameters)

Some claims add solid-state requirements that can materially affect freedom-to-operate if a competitor uses a different polymorph or different hydrate level:

Crystallinity: Claims 3-4 and 16-17
Crystalline purity threshold: Claims 5 (≥ about 95%) and 18 (≥ about 95%)
Powder diffraction pattern requirement: Claims 6 and 19 (Cu-Kα at ~25°C using FIG. 1 and FIG. 2, respectively)
Lattice parameters + space group constraints:
- Anhydrous salt: Claim 7
- monoclinic system; P 21/C or P 21/M
- measured with Mo-Kα at ~25°C
- lattice: a ~ 16.4460 Å, b ~ 21.4010 Å, c ~ 5.3050 Å, β ~ 109°
- Trihydrate salt: Claim 20
- monoclinic system; P 21/C or P 21/M
- measured with Mo-Kα at ~25°C
- lattice: a ~ 8.2490 Å, b ~ 29.9840 Å, c ~ 12.5070 Å, β ~ 105°
Chemical purity thresholds:
- Anhydrous salt: Claims 9-11 set about 97%, 98%, or 100% chemical purity
- Trihydrate salt: Claims 22-24 set about 97%, 98%, or 100% chemical purity

These are the claims most likely to be the focal point in validity and infringement testing because they define objective powder/diffraction and purity metrics.

4) Route and dosage form layers

Claims 12-13 and 25-26 add route/dosage language:

Oral administration: Claims 12 (anhydrous) and 25 (trihydrate)
Parenteral administration: Claims 13 (anhydrous) and 26 (trihydrate)

This means the patent does not confine the product to one route. A company can still be caught by a composition claim even if it sells oral vs parenteral, as long as the salt identity and excipient set match the claim.

5) Use claims: species-agnostic bacterial infection treatment

Claims 27-32 are “method of treating” bacterial infection in:

fish or a mammal (independent use claims 27 and 30)

Sub-claims:

Method administered to a mammal: Claims 28 and 31
Therapeutically acceptable amount range: Claims 29 and 32
0.03 to about 200 mg/kg body weight

In practice, the existence of the broad independent use claims (fish or mammal) and then a mammal-specific subset creates multiple infringement theories depending on label and indication.

What is the precise scope by claim group?

A. Composition claims for the anhydrous salt

Claim(s)	What is required	Coverage impact
1	Therapeutic composition containing the anhydrous salt + excipient from enumerated list	Broadest composition anchor
2	Salt present at therapeutically acceptable amount	Dose flexibility for infringement
3-4	Salt is crystalline; has substantial crystalline purity	Requires solid-state matching
5	Crystalline purity at least about 95%	Testable quantitative threshold
6	Powder diffraction pattern matches FIG. 1 (Cu-Kα, ~25°C)	Requires specific PXRD signature
7	Lattice params a/b/c and β; monoclinic; space group P 21/C or P 21/M; Mo-Kα	Strong crystallographic constraints
8-11	Salt has substantial chemical purity; chemical purity at about 97% / 98% / 100%	Enforces chemical grade constraints
12	Composition is orally administered dosage form	Adds route-specific embodiment
13	Composition is parenterally administered dosage form	Adds route-specific embodiment

B. Composition claims for the trihydrate salt

Claim(s)	What is required	Coverage impact
14	Therapeutic composition containing the trihydrate salt + excipient from enumerated list	Separate enforceable anchor
15	Salt present at therapeutically acceptable amount	Same dosing flexibility
16-17	Salt crystalline; substantial crystalline purity	Solid-state condition
18	Crystalline purity at least about 95%	Quantified threshold
19	Powder diffraction matches FIG. 2 (Cu-Kα, ~25°C)	Requires specific PXRD signature
20	Lattice params a/b/c and β; monoclinic; P 21/C or P 21/M; Mo-Kα	Crystallography-specific
21-24	Salt has substantial chemical purity; chemical purity about 97% / 98% / 100%	High purity requirements
25	Oral dosage form	Route-specific
26	Parenteral dosage form	Route-specific

C. Method-of-use claims

Claim(s)	What is required	Coverage impact
27	Administer composition (anhydrous salt) for bacterial infection in fish or mammal	Broad indication and species scope
28	Administered to a mammal	Narrows to mammal use
29	Dose range 0.03 to 200 mg/kg	Creates a quantitative infringement window tied to dosing
30	Administer composition (trihydrate salt) for bacterial infection in fish or mammal	Parallel method coverage
31	Mammal use	Mammal subset
32	Dose range 0.03 to 200 mg/kg	Dose-limited subset

How broad is enforceable coverage in practice?

1) Salt form is the key hinge

If a competitor uses:

the same salt identity but a different hydrate state/polymorph not meeting the diffraction/lattice claims, they may still fall under the broadest composition claim(s) if those claims do not require the specific crystalline characterization. Here, the “crystalline purity / diffraction / lattice” requirements appear only in dependent claims. The independent composition claim (Claim 1 for anhydrous; Claim 14 for trihydrate) already requires the salt itself but does not explicitly require the diffraction or purity thresholds.

So enforcement leverage is layered:

easy-to-assert: claim 1/14 if product contains the claimed salt form as defined in the claim
harder-to-assert or higher confidence: dependent claims if product can be pinned to PXRD patterns, lattice parameters, and purity

2) Excipient scope is broad but not universal

The excipient set is enumerated. If a product uses an excipient outside the list, it can avoid literal infringement of the composition claims that require “an excipient selected from the group consisting of” that list. The claims do not say “pharmaceutically acceptable excipient.” They use a specific list. That gives design-around leverage via excipient selection.

3) Routes are explicitly covered

Both oral and parenteral dosage forms are enumerated for each salt form. A manufacturer cannot easily avoid the patent by switching route alone.

4) Indication and species are explicitly covered

“Bacterial infection in fish or a mammal” covers companion animal, livestock, aquaculture, and potentially broader antimicrobial therapeutic contexts if claim construction supports inclusion.

What does this mean for the patent landscape?

1) Landscape structure: composition + solid-state + use

US 8,648,093 has a classic structure seen in solid-form antimicrobial programs:

an active salt identification
an excipient framework
solid-form dependent claims anchored to PXRD and lattice parameters
use claims that cover broad species and a dosing band

This structure typically implies that the patent portfolio in the same family (if present) will separate into:

new solid forms (anhydrous vs hydrate)
formulation embodiments
method-of-use and/or dosing windows

Even without viewing the family members, the claim architecture indicates the patent is intended to protect:

commercial drug substance as solid-state
marketed drug product as formulation
label indication as use

2) Likely enforcement targets inside the value chain

The claim set supports enforcement against:

drug product containing the claimed salt in the specified excipient framework
solid-state supply chain if product testing links the intermediate to the PXRD/lattice specs
label and dosing if method claims are asserted based on prescribing information or veterinary administration

3) Design-around levers

Based on the literal claim drafting, the most direct levers are:

solid form: use a different hydrate level or polymorph that does not meet the dependent solid-state characterization
excipient selection: choose excipients not listed in the “consisting of” set
route: no obvious route-based design-around because both oral and parenteral are claimed, but if a product uses a route not encompassed by oral/parenteral characterization in claim construction, that could matter
dose: avoid the 0.03 to 200 mg/kg band if method-of-use claims are asserted with dose limitations (though broad method claims without the dose range exist)

4) Litigation utility of diffraction and purity claims

Claims 6-7 and 19-20 (PXRD and lattice parameters) and claims 5/18 and 9-11/22-24 (crystalline and chemical purity thresholds) are the most evidentiary-heavy components. In infringement practice, they provide objective test targets that can drive:

infringement testing protocols
validity challenges based on prior art solid forms and characterization differences
settlement leverage if product testing can be made to “pass” or “fail” the thresholds

Claim-by-claim risk map for a competitor entering the US market

If the competitor sells an oral or parenteral product containing the anhydrous or trihydrate salt

Risk is high because:

composition claims 1/14 capture both route embodiments via dependent claims 12-13 and 25-26
method claims cover fish or mammal bacterial infection
dose range exists but does not eliminate exposure from broader method claims

If the competitor formulates with only excipients from the listed set

Risk remains high because excipient selection is already “allowed” by the claim list.

If the competitor uses excipients outside the enumerated list

They may avoid composition claim literal infringement if “excipient selected from the group consisting of” is strictly construed. This is one of the few plausible ways to reduce literal composition coverage.

If the competitor uses a different solid form

If their solid form does not correspond to the anhydrous or trihydrate salt as claimed, they can potentially avoid the salt identity requirement of independent composition claims. If they match the salt identity but differ in crystalline purity or PXRD signature, dependent claims become the main battleground.

Key Takeaways

US 8,648,093 protects two salt forms of the defined quinolinecarboxylate active with D-glucitol: anhydrous (Claims 1-13) and trihydrate (Claims 14-26).
The formulation scope is broad across oral and parenteral dosage forms and uses a large but enumerated excipient list.
The patent uses solid-state characterization layers (PXRD patterns, lattice parameters/space group, and purity thresholds) to create testable dependent claim hooks.
The method claims cover bacterial infection in fish or mammals with a 0.03 to 200 mg/kg dosing band appearing in dependent claims.
The most direct design-arounds are excipient substitution (outside the enumerated list) and solid-form selection (avoid the claimed anhydrous vs trihydrate identification and dependent solid-state specifications).

FAQs

1) Does the patent require a specific dosage form (tablet vs injection) to be infringed?

Yes for the route-specific dependent claims, but the independent composition coverage is not limited to a particular route; dependent claims explicitly cover oral (Claims 12, 25) and parenteral (Claims 13, 26).

2) Are crystalline purity and PXRD required for all coverage?

No. Crystalline purity (Claims 5, 18) and PXRD/lattice constraints (Claims 6-7, 19-20) are in dependent claims. Independent composition claims require the salt identity plus the listed excipient, not the diffraction or purity metrics.

3) Is the method of use limited to mammals only?

No. Independent method claims cover fish or a mammal (Claims 27, 30). Mammal-only is added in dependent claims (Claims 28, 31).

4) Is the dosing range mandatory for method-of-use infringement?

The 0.03 to 200 mg/kg range appears in dependent claims (Claims 29 and 32). Independent method claims exist without that range limitation.

5) What is the main practical lever to avoid composition-claim exposure?

Excipient selection. The composition claims use an excipient list framed as “selected from the group consisting of” a set of enumerated materials, so using excipients outside that set can reduce literal coverage.

References

[1] U.S. Patent No. 8,648,093 (claim text provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2582954	⤷ Start Trial
Cyprus	1125048	⤷ Start Trial
Denmark	3056492	⤷ Start Trial
European Patent Office	1802607	⤷ Start Trial
European Patent Office	3056492	⤷ Start Trial
European Patent Office	3957632	⤷ Start Trial
Spain	2901955	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,648,093

Summary for Patent: 8,648,093